---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-019747"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-06-10T23:59:59+00:00"
generated_at: "2026-06-01T05:18:37.968119+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Monopar presents preclinical uPAR-targeted radiopharma data at SNMMI; Phase 1 trial ongoing

## Summary
- Data show robust tumor uptake of MNPR-101-Zr in triple-negative breast, colorectal, and pancreatic cancer mouse models.
- Construct optimized for higher tumor uptake and stability with minimal bone and healthy tissue accumulation.
- First-in-human Phase 1 imaging/dosimetry trial in advanced cancer patients recently initiated led by Prof. Rodney Hicks.
- Trial details available on ClinicalTrials.gov under identifier NCT06337084.

## SEC filing metadata
- accession: 0001437749-24-019747
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924019747/0001437749-24-019747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924019747/mnpr20240608c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-019747
- JSON: https://secwatch.observer/filing/0001437749-24-019747.json
- Plain text: https://secwatch.observer/filing/0001437749-24-019747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.